FDA Approves Ruxience (rituximab-pvvr), a Biosimilar to Rituxan
FDA Approves Ruxience (rituximab-pvvr), a Biosimilar to Rituxan Print this page July 23, 2019 – Pfizer Inc. today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab),1 for the treatment of adult patients with non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis… Read More »